The National Institute for Health and Care Excellence (NICE) recommends that Merck and Pfizer's immunotherapy bavenio (avelumib) be combined with Inlyta (axinitib) for first-line treatment syntil-end renal cell carcinoma (RCC). The prognosis of patients with late
RCC is poor, with a five-year survival rate of only 12%, so more first-line treatment options are urgently needed.
picture source: Bavencio is an immune checkpoint inhibitor for PD-L1, while aschitinib is a strong and highly selective tyrosine kinase inhibitor that acts on vascular endothelial growth factor receptors (VEGFR) 1, 2 and 3.
the two drugs play complementary anti-tumor effects on two key pathways of tumor growth. in the JAVELIN Renal 101 study,
, the combination of drugs reduced the risk of disease progression or death by 31% and the median progression-free survival by 5.3 months, regardless of PD-L1 status.
research is under way to determine the overall survival benefits. Professor Amit Bahl, an expert in kidney cancer at
, said: "This positive recommendation from NICE provides an effective and well-tolerated treatment option for patients with advanced kidney cancer.
combination can improve outcomes in patients with advanced kidney cancer, immunotherapy and tyrosine kinase inhibitors provide new treatment options for patients.